Pharmacoeconomic analysis of the use of ibrutinib in therapy of the first line of a chronic lymphocytic leukaemia for patients with 17p deletion
We have performed the first-ever comparative pharmacoeconomic analysis in a Russian context of ibrutinib in the first line of therapy of chronic lymphocytic leukemia at patients with a 17p deletion. Research was conducted from a position of the state health system by means of mathematical modeling....
-д хадгалсан:
| Үндсэн зохиолчид: | , , , |
|---|---|
| Формат: | Ном |
| Хэвлэсэн: |
Izdatelstvo OKI,
2018-05-01T00:00:00Z.
|
| Нөхцлүүд: | |
| Онлайн хандалт: | Connect to this object online. |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
Интернэт
Connect to this object online.3rd Floor Main Library
| Зохиогчийн тэмдэгт: |
A1234.567 |
|---|---|
| Хуулбар 1 | Бэлэн |